Inselmann et al. noted that a higher CML-pDC count at diagnosis was associated with a poorer severity of the molecular response to nilotinib unless nilotinib therapy was combined with IFN (CML-V study), which strongly decreased the total number of circulating pDC, including CD86+ pDC [133]. This evidence concerns the gene CD86 and chronic myelogenous leukemia, BCR-ABL1 positive.